Adocia Future Growth

Future criteria checks 6/6

Adocia is forecast to grow earnings and revenue by 104.5% and 84.4% per annum respectively.

Key information

104.5%

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	29.3%
Revenue growth rate	84.4%
Future return on equity	75.1%
Analyst coverage	Low
Last updated	25 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

ENXTPA:ADOC - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	86	40	41	N/A	1
12/31/2024	50	27	27	N/A	1
12/31/2023	6	-21	N/A	N/A	N/A
9/30/2023	8	-21	N/A	N/A	N/A
6/30/2023	11	-21	-12	-11	N/A
3/31/2023	14	-14	-13	-13	N/A
12/31/2022	17	-7	-15	-15	N/A
9/30/2022	16	-7	-17	-17	N/A
6/30/2022	14	-8	-20	-19	N/A
3/31/2022	10	-15	-20	-19	N/A
12/31/2021	6	-23	-20	-19	N/A
9/30/2021	6	-22	-20	-20	N/A
6/30/2021	6	-22	-21	-21	N/A
3/31/2021	6	-23	-22	-21	N/A
12/31/2020	7	-23	-22	-22	N/A
9/30/2020	7	-20	-11	-10	N/A
6/30/2020	7	-18	1	1	N/A
3/31/2020	8	-18	-6	-4	N/A
12/31/2019	8	-19	-12	-10	N/A
9/30/2019	15	-17	-23	-21	N/A
6/30/2019	23	-16	-35	-33	N/A
3/31/2019	38	-4	-15	-13	N/A
12/31/2018	54	8	6	6	N/A
9/30/2018	47	1	4	5	N/A
6/30/2018	40	-5	2	3	N/A
3/31/2018	34	-7	-11	-9	N/A
12/31/2017	27	-9	-24	-22	N/A
9/30/2017	32	-3	N/A	-15	N/A
6/30/2017	38	3	N/A	-7	N/A
3/31/2017	34	-2	N/A	-10	N/A
12/31/2016	30	-8	N/A	-13	N/A
9/30/2016	37	-3	N/A	-11	N/A
6/30/2016	44	2	N/A	-10	N/A
3/31/2016	44	7	N/A	-8	N/A
12/31/2015	45	13	N/A	-6	N/A
9/30/2015	32	2	N/A	10	N/A
6/30/2015	19	-8	N/A	27	N/A
3/31/2015	12	-15	N/A	29	N/A
12/31/2014	4	-21	N/A	31	N/A
9/30/2014	6	-13	N/A	7	N/A
6/30/2014	8	-5	N/A	-17	N/A
3/31/2014	8	-5	N/A	-14	N/A
12/31/2013	9	-4	N/A	-11	N/A
9/30/2013	7	-7	N/A	-5	N/A
6/30/2013	6	-9	N/A	0	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ADOC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.1%).

Earnings vs Market: ADOC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ADOC is expected to become profitable in the next 3 years.

Revenue vs Market: ADOC's revenue (84.4% per year) is forecast to grow faster than the French market (5.8% per year).

High Growth Revenue: ADOC's revenue (84.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ADOC's Return on Equity is forecast to be very high in 3 years time (75.1%).

Adocia Future Growth

Future criteria checks 6/6

Key information

Recent future growth updates

Price target increased by 73% to €9.70

Price target decreased by 35% to €5.60

Price target increased to €9.80

Forecast breakeven date moved forward to 2022

Analysts update estimates

Recent updates

Full year 2023 earnings released

Third quarter 2023 earnings released

New minor risk - Financial data availability

Adocia SA to Report Q1, 2024 Results on May 14, 2024

Adocia SA's (EPA:ADOC) Shareholders Might Be Looking For Exit

Price target increased by 73% to €9.70

Adocia Reveals Promising Preclinical Data on Adocia Islets for Cell Therapy of Diabetes

New major risk - Shareholder dilution

First half 2023 earnings released

Adocia SA announced that it expects to receive €10 million in funding from Bpifrance Investissement SAS, Vester Finance SA and other investors

Price target decreased by 35% to €5.60

Adocia SA to Report First Half, 2023 Results on Sep 18, 2023

Adocia SA Announces the Successful Phase 1 Study for Biochaperone® Lispro with Partner Tonghua Dongbao

Price target increased to €9.80

Adocia Sa Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes Using M1pram in A Post-Hoc Analysis

First half 2022 earnings released: EPS: €0 (vs €1.51 loss in 1H 2021)

ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell(R) Islets for the Treatment of Type 1 Diabetes

Adocia SA, Annual General Meeting, Jun 28, 2022

Forecast breakeven date moved forward to 2022

ADOCIA Announces First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao

Adocia Announces the First Patient Dosed in the BioChaperone® Lispro Phase 3 Program with Partner Tonghua Dongbao

Insufficient new directors

Full year 2021 earnings released

Adocia SA Announces Start of 3 Clinical Studies for BioChaperone® Combo with Partner Tonghua Dongbao

Adocia Files Patent for Technology to Enable Oral Drug Delivery of Peptides

First half 2021 earnings released

Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes

Adocia SA Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps

Is Adocia (EPA:ADOC) A Risky Investment?

Full year 2020 earnings released: €3.30 loss per share (vs €2.68 loss in FY 2019)

Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes

Adocia Announces Positive Clinical Results Confirming the Ultra-Rapid Profile of a BioChaperone® Lispro Formulation Containing Insulin from Partner Tonghua Dongbao

Adocia Files Patent on a Hydrogel Scaffold for Cell Therapy in the Treatment of Type 1 Diabetes

New 90-day high: €8.65

Adocia SA to Report First Half, 2021 Results on Sep 07, 2021

New 90-day high: €8.35

Is Adocia (EPA:ADOC) Using Debt In A Risky Way?

New 90-day low: €7.05

Analysts update estimates

New 90-day low: €7.38

Adocia SA(ENXTPA:ADOC) dropped from S&P Global BMI Index

New 90-day low - €7.79

New 90-day low - €7.93

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies